20 December 2023
Neuren Pharmaceuticals (NEU): It Keeps Getting Better
NEU released impressive efficacy and safety results from the first of four single-arm Phase 2 trials evaluating NNZ-2591 (n=18).
12 December 2023
IPD Goup (IPG): Lightning in a bottle
IPD has announced the acquisition of CMI Operations for an upfront $92.1m and contingent consideration of up to $8.9m. Our revised PT is $5.75 (prev. $5.50) with our Buy recommendation remaining unchanged.
12 December 2023
Regis Resources Ltd (RRL): Hedge book overhang removed
RRL has announced the closure of its gold hedge book for a cost of A$98m. Our NPV-based valuation is up 3%, to $2.37/sh and we retain our Buy recommendation.
30 November 2023
Life360 (360): Better to be safe
We have reviewed our Life360 forecasts post the release of the 3Q2023 result a couple of weeks ago and made some minor adjustments. We maintain a Buy recommendation and have decreased our Price Target by 2% to $11.00.
30 November 2023
IDP Education (IEL): O’ Canada
We have updated each valuation for IPD Education used in the determination of our PT for the forecast changes and recent market movements. We upgrade to a Buy recommendation and a price target of $27.00.
22 November 2023
Australian Agricultural Co (AAC): More than meating expectations
AAC reported 1H24 Operating EBITDA ahead or our expectations at $30.1m. Our Buy rating remains unchanged.